Tyson Falls on 3Q Results; Bristol-Myers Squibb Surges on Potential Acquisition | Stock Movers

Tyson Foods experienced a dip in its stock after releasing its third-quarter 2026 results on August 3, 2026. The company reported sales of $13.87 billion, a slight decrease from $13.88 billion in the prior year. Operating income for the quarter was $362 million, an increase from $260 million year-over-year. Adjusted earnings per share (EPS) were $0.99, up from $0.91 in the same quarter last year. Despite the increase in income and adjusted EPS, the company's free cash flow was $913 million, down $16 million from the prior year. Tyson Foods also reduced its total debt by $824 million and maintained a liquidity of $4.0 billion as of June 27, 2026. The company anticipates steeper losses in its beef segment as volumes decline.

In contrast, Bristol Myers Squibb's stock surged by approximately 8% in premarket trading on August 3, 2026, driven by speculation of initial discussions with AstraZeneca. The market capitalization of Bristol Myers increased by an estimated $10.7 billion on the news. This positive movement was further bolstered by Bristol Myers Squibb surpassing LSEG forecasts and raising its 2026 guidance. The company reported a 6% increase in second-quarter revenue to $12.97 billion and a 40% gain in adjusted earnings to $2.04 per share. Its 2026 revenue outlook was raised to $49.0-$50.0 billion, up from $46.0-$47.5 billion, representing a 5.9% midpoint increase. The adjusted EPS outlook for 2026 also climbed to $6.75-$7.00, an increase of 10.9% at the midpoint from the previous $6.05-$6.35. AstraZeneca's value, however, decreased by an estimated $16.9 billion, resulting in an initial net loss of $6.2 billion for the combined entities based on market caps from Friday.

The improved individual figures and increased guidance from Bristol Myers Squibb contribute to a standalone value, signaling optimism for the company. While Reuters could not confirm ongoing talks between Bristol Myers and AstraZeneca, the market reacted positively to the prospect. Bristol Myers' strong earnings momentum and revised outlook position the company favorably, even without a confirmed deal, as it eases pressure to agree to unfavorable acquisition terms.